{"name": "Impax Laboratories",
 "permalink": "impax-laboratories",
 "crunchbase_url": "http://www.crunchbase.com/company/impax-laboratories",
 "homepage_url": "http://www.impaxlabs.com/",
 "blog_url": "",
 "blog_feed_url": "",
 "twitter_username": "",
 "category_code": "biotech",
 "number_of_employees": null,
 "founded_year": null,
 "founded_month": null,
 "founded_day": null,
 "deadpooled_year": null,
 "deadpooled_month": null,
 "deadpooled_day": null,
 "deadpooled_url": null,
 "tag_list": "",
 "alias_list": "",
 "email_address": "cs@impaxlabs.com",
 "phone_number": "(510) 476-2000",
 "description": "",
 "created_at": "Fri Dec 17 04:50:21 UTC 2010",
 "updated_at": "Fri Dec 17 04:52:31 UTC 2010",
 "overview": "\u003Cp\u003EImpax Laboratories, Inc. is a technology-based, specialty pharmaceutical company. The Company is focused on the development and commercialization of bioequivalent and brand-name pharmaceuticals. In the generic pharmaceuticals market, the Company focuses on controlled-release generic versions of brand-name pharmaceuticals, covering a range of therapeutic areas. In the brand-name pharmaceuticals market, the Company is developing products for the treatment of central nervous system (CNS) disorders. The Company\u00e2\u20ac\u2122s brand-name product portfolio consists of development-stage projects to which the Company applies its formulation and development expertise to develop differentiated, modified, or controlled-release versions of marketed drug substances. It operates in two segments: Global Pharmaceuticals Division (Global Division) and the Impax Pharmaceuticals Division (Impax Division). \u003C/p\u003E",
 "image":
  {"available_sizes":
    [[[150,
       36],
      "assets/images/resized/0011/4412/114412v1-max-150x150.png"],
     [[195,
       47],
      "assets/images/resized/0011/4412/114412v1-max-250x250.png"],
     [[195,
       47],
      "assets/images/resized/0011/4412/114412v1-max-450x450.png"]],
   "attribution": null},
 "products":
  [],
 "relationships":
  [{"is_past": false,
    "title": "President, CEO, Director ",
    "person":
     {"first_name": "Larry",
      "last_name": "Hsu",
      "permalink": "larry-hsu",
      "image": null}},
   {"is_past": false,
    "title": "CFO",
    "person":
     {"first_name": "Arthur",
      "last_name": "A. Koch Jr.",
      "permalink": "arthur-a-koch-jr",
      "image": null}}],
 "competitions":
  [],
 "providerships":
  [],
 "total_money_raised": "$0",
 "funding_rounds":
  [],
 "investments":
  [],
 "acquisition": null,
 "acquisitions":
  [],
 "offices":
  [{"description": "",
    "address1": "31047 Genstar Road",
    "address2": "",
    "zip_code": "94544",
    "city": "Hayward",
    "state_code": "CA",
    "country_code": "USA",
    "latitude": null,
    "longitude": null}],
 "milestones":
  [{"description": "Impax snares $186M deal from GSK on late-stage Parkinson's drug",
    "stoned_year": 2010,
    "stoned_month": 12,
    "stoned_day": 16,
    "source_url": "http://www.fiercebiotech.com/story/impax-snares-186m-deal-gsk-late-stage-parkinsons-drug/2010-12-16?utm_medium=rss\u0026utm_source=rss",
    "source_text": "",
    "source_description": "Impax snares $186M deal from GSK on late-stage Parkinson's drug",
    "stoneable_type": "Company",
    "stoned_value": null,
    "stoned_value_type": null,
    "stoned_acquirer": null,
    "stoneable":
     {"name": "Impax Laboratories",
      "permalink": "impax-laboratories"}}],
 "ipo":
  {"valuation_amount": null,
   "valuation_currency_code": "USD",
   "pub_year": null,
   "pub_month": null,
   "pub_day": null,
   "stock_symbol": "NASDAQ:IPXL"},
 "video_embeds":
  [],
 "screenshots":
  [],
 "external_links":
  []}